University of Patras
Η αντιδραστικότητα των αιμοπεταλίων σε ασθενείς που λαμβάνουν αντιρετροϊκή αγωγή
Abstract
dc:descriptionINTRODUCTION – AIM: People living with HIV (PLWHIV) present an increased risk of adverse cardiovascular events. We aimed to assess whether antiretroviral therapy (ART) pharmacologically enhances platelet reactivity and platelet activation intensity, and explore the potential association with underlying inflammatory status. METHOD: This was a cross-sectional cohort study carried out among PLWHIV on diverse ART regimens. Platelet reactivity was assessed using the bedside point-of- care Verify Now assay, inP2Y12 reaction units (PRU). Levels of major inflammatory markers and whole blood parameters were also evaluated. RESULTS: In total, 71 PLWHIV, 59 on ART and 22 healthy controls, were included in this study. PRU values were significantly elevated in PLWHIV compared to controls [Mean; 257.85 vs.196.67, p < 0.0001], but no significant differences were noted between ART-naïve or ART experienced PLWHIV, or between TAF/TDF and ABC based regimens, similar to systemic inflammatory response. However, within-group analysis showed that PRUs were significantly higher in ABC/PI vs ABC/INSTI or TAF/TDF + PI patients, in line with levels of IL-2. PRU values did not correlate strongly with CD4 counts, viral load, or cytokine values. Platelet reactivity and platelet activation intensity were shown to be increased in PLWHIV, but they did not appear to be related to ART initiation, similar to the underlying systemic inflammatory response. CONCLUSIONS: HIV infection per se, as well as ART, have been associated with increased thrombotic risk, leading to adverse cardiovascular events. Underlying mechanisms driving this phenomenon remain elusive, while the role of platelets is currently under investigation. We found increased platelet activation and intensity in PLWHIV, even though platelet activity as tested here does not seem to significantly differ between TAF/TDF and ABC based combinations, pushing focus to other pathways and mediators. In this setting, one would be worth wondering whether in PLWHIV with no increased cardiovascular risk, but still elevated platelet activation, the use of antiplatelets would be of benefit, as in acute bacterial infection. Or, if an increased dose or use of more potent antiplatelet regimens would be necessary in patients with history of cardiovascular disease or receiving PIs, in view of recent findings of high on treatment platelet reactivity in PLWHIV. Whether platelet reactivity and activation intensity could in the future represent a reliable surrogate marker for major adverse cardiovascular events remains to be seen.
Degree
thesis:*- Grantor dc:publisher
- University of Patras
- Year dc:date
- 2023
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- kolosaka, Martha
- Κολόσακα, Μάρθα
Subjects
dc:subject × 10Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/54522